{"id":"sim0270","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"SIM0270 is an investigational drug in Phase 3 development by Jiangsu Simcere Pharmaceutical. Limited public information is available regarding its precise molecular mechanism and target. Additional clinical trial data would be needed to fully characterize its mechanism of action.","oneSentence":"SIM0270 is a small molecule inhibitor targeting a specific molecular pathway involved in disease pathogenesis, though the exact mechanism requires further clarification.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:42.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07357610","phase":"PHASE1","title":"An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2026-01-05","conditions":"Healthy Adult Participants","enrollment":60},{"nctId":"NCT06680921","phase":"PHASE3","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":460},{"nctId":"NCT06536036","phase":"PHASE1","title":"Evaluate the Effects of Food on the Pharmacokinetics of SIM0270","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-07-23","conditions":"Healthy Participants","enrollment":16},{"nctId":"NCT05293964","phase":"PHASE1","title":"Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2022-05-18","conditions":"Breast Cancer","enrollment":214},{"nctId":"NCT06654791","phase":"PHASE1","title":"Mass Balance Clinical Trial of SIM0270","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-10-17","conditions":"Healthy Participants","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCR6852"],"phase":"phase_3","status":"active","brandName":"SIM0270","genericName":"SIM0270","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}